Description

Guardant Health Tops $1 Billion TTM Revenue As Test Volumes Surge!

Guardant Health reported a strong first quarter for 2026, highlighted by robust revenue growth across its key business segments: Oncology, Biopharma & Data, and Screening. Total revenue reached $302 million, a 48% increase year-over-year, marking the fastest annual growth rate for the company in five years and surpassing a trailing 12-month revenue milestone of $1 billion. This growth was attributed to increasing test volumes and broad-based adoption of its diagnostic products. In Oncology, revenue grew 36% to $205 million, supported by a 47% increase in test volume to approximately 86,000 tests. Growth was widespread across the portfolio, including a 30% volume rise for Guardant360 Liquid and a strong performance for Guardant360 Tissue, which is expanding following recent whole transcriptome RNA upgrades. Reveal, a product focused on minimal residual disease (MRD) detection and therapy response monitoring, showed outstanding volume growth exceeding 100%, driven by adoption across multiple indications.